Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company that develops and commercializes medicines, with a focus on small-molecule drug candidates and internally discovered biological targets. Its approved drug, INPEFA (sotagliflozin), is an oral treatment to reduce cardiovascular death,… From the company’s description.
Over the twelve months to Sep 30, 2026, Lexicon Pharmaceuticals, Inc. reported revenue of $38.54M, down 45.6% from a year earlier, and a net loss of $62.35M. Its operating margin was −147.4%, and operations used $49.23M in cash. In fiscal 2025, it reported revenue of $49.80M, up 60.2% from fiscal 2024, and a net loss of $50.34M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lexicon Pharmaceuticals, Inc. does
In the company’s own words
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) is a biopharmaceutical company that develops and commercializes medicines, with a focus on small-molecule drug candidates and internally discovered biological targets. Its approved drug, INPEFA (sotagliflozin), is an oral treatment to reduce cardiovascular death, heart-failure hospitalization and urgent heart-failure visits in eligible adults; the company sells it in the United States through wholesalers and a mail-order pharmacy. Lexicon is also developing sotagliflozin for hypertrophic cardiomyopathy and pursuing its use in type 1 diabetes. Its pipeline includes pilavapadin for neuropathic pain and LX9851 for obesity and related cardiometabolic disorders, which is licensed worldwide to Novo Nordisk; additional programs remain in preclinical research. The company conducts research, development and commercialization activities itself and through collaborations, including a license with Viatris for sotagliflozin in certain territories. Lexicon reports one operating business focused on drug research, development and commercialization. It was incorporated in 1995 and listed on Nasdaq in 2000. Its website is www.lexpharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- THE WOODLANDS, TX
- Fiscal year end
- December
- CIK
- 1062822
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lexicon Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lexicon Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lexicon Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lexicon Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lexicon Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”